Literature DB >> 1447396

Advances in the diagnosis of adverse drug reactions.

C A Naranjo1, N H Shear, K L Lanctôt.   

Abstract

The clinician plays a key role in the detection and diagnosis of adverse drug reactions (ADRs). The diagnosis of ADRs, however, is a complex task. In the past, there were no systematically applied diagnostic criteria for ADRs, no formal methods of case analysis, no standardized epidemiologic approaches, and a limited knowledge of mechanisms. This resulted in the overdiagnosis of ADRs, which has negative consequences such as limiting treatment options. Recently, there have been various improvements in the diagnosis of ADRs, such as the development of standardized decision aids and of in vitro diagnostic tests. This article briefly reviews some of this knowledge, discusses the role of in vivo and in vitro rechallenge, and summarizes a probabilistic approach for collecting relevant information and diagnosing ADRs. The intention is to increase awareness of the different approaches for diagnosing ADRs as well as to stimulate researchers to continue to collect pharmacoepidemiologic information, study the pharmacologic, immunologic, and genetic factors involved in the pathogenesis of drug reactions, and develop and test new diagnostic instruments under various clinical conditions.

Entities:  

Mesh:

Year:  1992        PMID: 1447396     DOI: 10.1002/j.1552-4604.1992.tb04635.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  29 in total

1.  Development of a combined system for identification and classification of adverse drug reactions: Alerts Based on ADR Causality and Severity (ABACUS).

Authors:  Yvonne Koh; Chun Wei Yap; Shu-Chuen Li
Journal:  J Am Med Inform Assoc       Date:  2010 Nov-Dec       Impact factor: 4.497

2.  A new algorithm to identify the causality of adverse drug reactions.

Authors:  Yvonne Koh; Shu Chuen Li
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Using computerized data to identify adverse drug events in outpatients.

Authors:  B Honigman; J Lee; J Rothschild; P Light; R M Pulling; T Yu; D W Bates
Journal:  J Am Med Inform Assoc       Date:  2001 May-Jun       Impact factor: 4.497

4.  Quetiapine-Induced Bradycardia Without QT Interval Prolongation in an Elderly Woman.

Authors:  André Janse; Radboud M Marijnissen
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

5.  Impact of medication reconciliation for improving transitions of care.

Authors:  Patrick Redmond; Tamasine C Grimes; Ronan McDonnell; Fiona Boland; Carmel Hughes; Tom Fahey
Journal:  Cochrane Database Syst Rev       Date:  2018-08-23

Review 6.  The epidemiology of serious adverse drug reactions among the elderly.

Authors:  P A Atkin; P C Veitch; E M Veitch; S J Ogle
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

7.  Thrombocytopenia associated with 5-aminosalicylate prodrug, olsalazine: is the devil still there?

Authors:  Yuefeng Rao; Feiyue Zheng
Journal:  Int J Clin Pharm       Date:  2013-04-27

8.  Safety of herbal products in Thailand: an analysis of reports in the thai health product vigilance center database from 2000 to 2008.

Authors:  Surasak Saokaew; Wimon Suwankesawong; Unchalee Permsuwan; Nathorn Chaiyakunapruk
Journal:  Drug Saf       Date:  2011-04-01       Impact factor: 5.606

9.  Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate.

Authors:  David A Dorr; Rachel Burdon; Dennis P West; Jennifer Lagman; Christina Georgopoulos; Steven M Belknap; June M McKoy; Benjamin Djulbegovic; Beatrice J Edwards; Sigmund A Weitzman; Simone Boyle; Martin S Tallman; Moshe Talpaz; Oliver Sartor; Charles L Bennett
Journal:  Clin Cancer Res       Date:  2009-05-19       Impact factor: 12.531

10.  Adverse events associated with rofecoxib therapy: results of a large study in community-derived osteoarthritic patients.

Authors:  Bernard Bannwarth; Richard Trèves; Liana Euller-Ziegler; Denis Rolland; Philippe Ravaud; Maxime Dougados
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.